*Take-home Points* * *Study Question:* Does twice-daily ensifentrine reduce the rate and/or risk of moderate/severe exacerbations in patients with COPD? * *Results:* In a pooled analysis of data from the phase 3 Ensifentrine as a Novel Inhaled Nebulized COPD Therapy (ENHANCE)-1 and ENHANCE-2 trials, *ensifentrine substantially reduced both the rate and the risk of exacerbations over 24 weeks of treatment.* * Treatment effects favoring ensifentrine were observed in all subgroups assessed: age, sex, race, background maintenance medication, history of bronchitis, baseline eosinophil count, COPD severity, and prior exacerbations (within the previous 15 months) subgroups. * *Interpretation:* These data support ensifentrine as a potential treatment option for the majority of patients with COPD who require additional or alternative treatment options to reduce exacerbation burden. *#enhance-2 Trial* *#ensifentrine* *#copd Exacerbation* *#medlung Talks 🫁* DOI: 10.1016/j.chest.2024.07.168